Mogrify develops in vivo reprogramming therapies that utilize a proprietary platform to identify key transcriptomic and epigenetic factors necessary for direct cellular conversion. This technology aims to restore lost cell types in patients with degenerative diseases, particularly in otology, ophthalmology, and diabetes, addressing significant unmet clinical needs.
Funding
$49.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many degenerative diseases result in the loss of specific cell types, leading to organ dysfunction and unmet clinical needs in areas like otology, ophthalmology, and diabetes. Current treatment options often fail to restore the lost cells directly in vivo.
Solution
Mogrify is developing a novel class of in vivo reprogramming therapies to regenerate functional cells lost due to degenerative diseases. The company's proprietary MOGRIFY® and epiMOGRIFY® platforms use a systematic, big-data driven approach to identify optimal combinations of transcription factors and growth factors needed for direct cellular reprogramming and maintenance of cell identity. These platforms leverage next-generation sequencing, gene regulatory, and epigenetic network data to predict factors required to produce any target cell type from any source cell type. This approach enables the company to enhance existing stem-cell forward programming methods or bypass development pathways altogether, affecting direct transdifferentiation between mature cell types.
Target Audience
The primary target audience includes patients suffering from degenerative diseases such as sensorineural hearing loss, vision loss, and diabetes, as well as pharmaceutical companies seeking co-development partnerships in regenerative medicine.
Features
- MOGRIFY® platform for direct cellular reprogramming using transcriptomic data
- epiMOGRIFY® platform for maintaining cell identity using epigenetic data
- Identification of optimal transcription factor combinations for cell conversion
- Prediction of growth factors required for target cell type production
- Ability to enhance stem-cell forward programming or bypass developmental pathways
- Focus on in vivo reprogramming for regenerative medicine applications
- Applicability across otology, ophthalmology, diabetes, and other degenerative diseases